Investigational drugs under development for the treatment of PTSD. (Q38378939)

2 September 2017

1 reference

title

Investigational drugs under development for the treatment of PTSD. (English)

1 reference

post-traumatic stress disorder

2 September 2017

main subject

0 references

5

Alexander Neumeister

Department of Psychiatry, New York University School of Medicine

0 references

Robert H Pietrzak

series ordinal

4

object named as

Robert H Pietrzak

1 reference

2 September 2017

Benjamin J Ragen

1

1 reference

2 September 2017

Jordan Seidel

series ordinal

2

1 reference

2 September 2017

Christine Chollak

series ordinal

3

1 reference

2 September 2017

language of work or name

English

0 references

publication date

14 March 2015

1 reference

Expert Opinion on Investigational Drugs

2 September 2017

published in

1 reference

2 September 2017

volume

24

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

659-672

1 reference

Posttraumatic stress disorder in the National Comorbidity Survey

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Effect of cognitive behavioral therapy on heart rate variability during REM sleep in female rape victims with PTSD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Partial PTSD versus full PTSD: an empirical examination of associated impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Adolescent posttraumatic stress disorder: an examination of factor structure reliability in two national samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Killing and latent classes of PTSD symptoms in Iraq and Afghanistan veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Posttraumatic stress disorder in female veterans with military and civilian sexual trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Examining the relation between combat-related concussion, a novel 5-factor model of posttraumatic stress symptoms, and health-related quality of life in Iraq and Afghanistan veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Support for a novel five-factor model of posttraumatic stress symptoms in three independent samples of Iraq/Afghanistan veterans: a confirmatory factor analytic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The dimensional structure of posttraumatic stress symptomatology in 323,903 U.S. veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Assessing the fit of the Dysphoric Arousal model across two nationally representative epidemiological surveys: The Australian NSMHWB and the United States NESARC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Evidence for a unique PTSD construct represented by PTSD's D1-D3 symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

DSM-5 PTSD's symptom dimensions and relations with major depression's symptom dimensions in a primary care sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Comorbidity of posttraumatic stress disorder, anxiety and depression: a 20-year longitudinal study of war veterans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The role of beta-endorphin in the pathophysiology of major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

An examination of the structure of posttraumatic stress disorder in relation to the anxiety and depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Linking in vivo brain serotonin type 1B receptor density to phenotypic heterogeneity of posttraumatic stress symptomatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Toward the future of psychiatric diagnosis: the seven pillars of RDoC

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Modulation of transmitter release via presynaptic cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

7,8-dihydroxyflavone, a TrkB receptor agonist, blocks long-term spatial memory impairment caused by immobilization stress in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Sleep disturbances as the hallmark of PTSD: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Review of the validity and significance of cannabis withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The effects of cannabinoids on the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Applying learning principles to the treatment of post-trauma reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Cannabinoid facilitation of fear extinction memory recall in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Amygdala FAAH and anandamide: mediating protection and recovery from stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Molecular characterization of a peripheral receptor for cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

21 January 2018

Sleep-inducing factors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Altered pain processing in veterans with posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Differentiation of pain ratings in combat-related posttraumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Modulation of anxiety through blockade of anandamide hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Formation and inactivation of endogenous cannabinoid anandamide in central neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Molecular diversity of glutamate receptors and implications for brain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Glutamate receptors in extinction and extinction-based therapies for psychiatric illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The intraoperative administration of ketamine to burned U.S. service members does not increase the incidence of post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Corticotropin-releasing factor modulates basal and stress-induced excitatory amino acid release in the locus coeruleus of conscious rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Pharmacology and functions of metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Pharmacological agents acting at subtypes of metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Unitary IPSPs enhance hilar mossy cell gain in the rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Modulation of GABAergic inhibition in the rat superior colliculus by a presynaptic group II metabotropic glutamate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Group II and III mGluRs-mediated presynaptic inhibition of EPSCs recorded from hippocampal interneurons of CA1 stratum lacunosum moleculare.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Group II and III metabotropic glutamate receptors and the control of the nucleus reticularis thalami input to rat thalamocortical neurones in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxioly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Endogenous Opioids: Biology and Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Association of in vivo κ-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Peptide kappa opioid receptor ligands: potential for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

κ-Opioid receptors within the nucleus accumbens shell mediate pair bond maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Induction of fear extinction with hippocampal-infralimbic BDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Acute stress and chronic stress change brain-derived neurotrophic factor (BDNF) and tyrosine kinase-coupled receptor (TrkB) expression in both young and aged rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Impaired fear extinction learning in adult heterozygous BDNF knock-out mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Brain-derived neurotrophic factor plasma levels in patients suffering from post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Activation of BDNF signaling prevents the return of fear in female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Oxytocin administration enhances controlled social cognition in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Oxytocin and autism: a systematic review of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Affiliation buffers stress: cumulative genetic risk in oxytocin-vasopressin genes combines with early caregiving to predict PTSD in war-exposed young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Central administration of oxytocin receptor ligands affects cued fear extinction in rats and mice in a timepoint-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Intranasal oxytocin as strategy for medication-enhanced psychotherapy of PTSD: salience processing and fear inhibition processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Prazosin for military combat-related PTSD nightmares: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

The role of hyperarousal in the manifestation of posttraumatic psychological distress following injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Dimensional structure and course of post-traumatic stress symptomatology in World Trade Center responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Risk for suicidal behaviors associated with PTSD, depression, and their comorbidity in the U.S. Army

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1020109

10.1517/13543784.2015.1020109

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference